Hepatitis C

Zakim and Boyer's Hepatology

Volumn , Issue , 2006, Pages 665-686

  Wright, Teresa L ^a   Manns, Michael P ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861975948     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3258-8.50037-1     Document Type: Chapter

References (140)

1. Management of hepatitis C: June 10-12, 2002. Hepatology 2002, 36:S3-S20. National Institutes of Health Consensus Development Conference Statement.
2. Global distribution of hepatitis A, B and C, 2001. Wkly Epidemol Rec 2002, 77:41-48. National Institutes of Health Consensus Development Conference Statement.
3. Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile delta: population description and HCV prevalence. Hepatology 2000, 32:111-115.
4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562.
5. Summary of notifiable diseases, United States, 1998. Morb Mortal Wkly Rep 1998, 47:1-39. National Institutes of Health Consensus Development Conference Statement.
6. Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepatitis 2000, 7:196-202.
7. Simmonds P. The origin and evolution of hepatitis viruses in humans. J Gen Virol 2001, 82:693-712.
8. Kim WR The burden of hepatitis C in the United States. Hepatology 2002, 36:S30-S34.
9. Armstrong GL, Simard EP, Wasley A, et al. The prevalence of hepatitis C (HCV) infection in the United States, 1999-2002. Hepatology 2004, 40:176A.
10. Kim WR, Poterucha JJ, Benson JT, Therneau TM The impact of competing risks on the observed rate of chronic hepatitis C progression. Gastroenterology 2004, 127:749-755.
11. El-Serag HB, Mason AC Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
12. El-Serag HB, Davila JA, Peterson NJ, McGlynn KA The continued increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
13. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000, 31:777-782.
14. Davila JA, Morgan TO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004, 127:1372-1380.
15. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001, 33:62-65.
16. Alter MJ Prevention of spread of hepatitis C. Hepatology 2002, 36:S93-S98.
17. Conry-Cantilena C, Gibble J, Melpolder J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996, 334:1691-1696.
18. Thomas D, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine 1995, 74:212-220.
19. Bell J, Batey RF, Crewe E, et al. Hepatitis C virus in intravenous drug users. Med J Aust 1990, 153:274-276.
20. Terrault NA Sexual activity as a risk factor for hepatitis C. Hepatology 2002, 36:S99-S105.
21. Roberts EA, Yeung L Maternal transmission of hepatitis C virus infection. Hepatology 2002, 36:S106-S113.
22. Strader DB, Wright TL, Thomas DL, Seeff LB Diagnosis, management and treatment of hepatitis C. AASLD practice guideline. Hepatology 2004, 39:1147-1171.
23. Seeff LB Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-S46.
24. Fattovitch G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 112:463-472.
25. Serfarty L, Aumaître H, Chazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998, 27:1435-1440.
26. Hu K-Q, Tong MJ The long-term outcomes of patients with compensated hepatitis C virus related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999, 29:1311-1316.
27. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000, 47:131-136.
28. Tong M, El-Farra N, Reikes A, Co R. Clinical outcomes after transfusion-associated hepatitis C infection. N Engl J Med 1995, 332:1463-1466.
29. Clinical outcomes after hepatitis infection from contaminated antiglobulin. N Engl J Med 1999, 340:1228-1233. National Institutes of Health Consensus Development Conference Statement.
30. Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000, 32:91-96.
31. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcomes of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999, 341:866-870.
32. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000, 132:105-111.
33. Desai MM, Zhuang P, Hennessy CH Surveillance of morbidity and mortality among older adults - United States, 1995-1996. Morb Mortal Wkly Rep 1999, 48:7-25.
34. Hser Y-I, Hoffman V, Grella CE, Anglin MD A 33-year follow-up of narcotic addicts. Arch Gen Psychiatry 2001, 58:503-508.
35. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:730-739.
36. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997, 349:825-832.
37. Wiley TE, Brown J, Chan J Hepatitits C virus infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002, 97:700-706.
38. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994, 331:1607-1611.
39. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000, 32:673-684.
40. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999, 30:1054-1058.
41. Hui JM, Sud A, Farrell G, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003, 125:1695-1704.
42. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31:828-833.
43. Monto A, Alonzo J, Watson J, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus and alcohol consumption. Hepatology 2002, 36:729-736.
44. Zarski JP, McHutchison J, Bronowicki JP, et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 2003, 38:307-314.
45. Monto A, Bostrom A, Pianko S, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004, 39:826-834.
46. Agnello V, Chung RT, Kaplan LM A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992, 327:1490-1495.
47. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 1991, 9:621-624.
48. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993, 328:465-470.
49. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993, 18:253-257.
50. Fargion S, Piperno A, Cappellini MD, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992, 16:1322-1326.
51. Stolzel U, Schuppan D, Tillmann HL, et al. Autoantibodies in porphyria cutanea tarda: a controlled study. J Hepatol 2000, 33:858-859.
52. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 29:328-333.
53. Dalekos GN, Wedemeyer H, Obermayer-Straub P, et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999, 30:366-375.
54. Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000, 32:91-96.
55. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125:80-88.
56. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002, 195:35-41.
57. Herzer K, Falk CS, Encke J, et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol 2003, 77:8299-8309.
58. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339-344.
59. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000, 6:578-582.
60. Bain C, Fatmi A, Zoulim F, et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001, 120:512-524.
61. Longman RS, Talal AH, Jacobson IM, et al. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 2004, 103:1026-1029.
62. Wiegend J, Potthoff A, Manns MP, et al. Acute hepatitis C infection: can immunology teach us the right way to treat?. Curr Hepatitis Rep 2004, 3:148-156.
63. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001, 194:1395-1406.
64. Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002, 169:3447-3458.
65. Cramp ME, Rossol S, Chokshi S, et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000, 118:346-355.
66. Pawlotsky JM Use and interpretation of virological tests for hepatitis C. Hepatology 2002, 36:S65-S73.
67. Pawlotsky JM Molecular diagnosis of viral hepatitis. Gastroenterology 2003, 122:1554-1568.
68. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004, 351:760-768.
69. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255-262.
70. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
71. Batts KP, Ludwig J Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995, 19:1409-1417.
72. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
73. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
74. Fontana RJ, Lok AS Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002, 36:S57-S64.
75. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986, 315:1575-1578.
76. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989, 321:1501-1506.
77. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
78. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
79. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
80. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
81. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
82. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004, 40:993-999.
83. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
84. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004, 127:1724-1732.
85. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126:1015-1023.
86. Poynard T, Schiff ER, Terg R, et al. Sustained virological response (SVR) in the EPIC3 trial: week 12 virology predicts SVR in previous interferon/ribavirin tretament failures receiving PEG-Intron/Rebetol (PR) weight based dosing (WBD). J Hepatol 2005, 42:S40-S41.
87. Curry M, Cardenas A, Afdhal NH Effect of maintenance PEG-Intron therapy on portal hypertension and its complications: results from the COPILOT study. J Hepatol 2005, 42:S40.
88. Edlin BR Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002, 36:S210-S219.
89. Nyamathi AM, Dixon EL, Robbins W, et al. Risk factors for hepatitis C virus infection among homeless adults. J Gen Intern Med 2002, 17:13-143.
90. Jonas MM Children with hepatitis C. Hepatology 2002, 36:S173-S178.
91. Brau N, Bini EJ, Shahidi A, et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 2002, 97:2071-2078.
92. Poles MA, Dieterich DT Hepatitis C virus/human immunodeficiency virus coinfection: clinical management issues. Clin Infect Dis 2000, 31:154-161.
93. Howell C, Jeffers L, Hoofnagle JH Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000, 119:1385-1396.
94. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39:1702-1708.
95. Muir AJ, Bornstein JD, Killenberg PG Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265-2271.
96. McHutchison JG, Ponard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000, 119:1317-1323.
97. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003, 36:491-498.
98. Sulkowski MS, Thomas DL Hepatitis C in the HIV-infected person. Ann Intern Med 2003, 138:197-207.
99. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
100. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
101. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
102. Tien PS Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs hepatitis C resource center program and the national hepatitis C program office. Am J Gastroenterol 2005, 100:1-17.
103. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-569.
104. Soto B, Sanchez-Ouijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997, 26:1-5.
105. Monto A, Dove LM, Bostrom A, et al. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005, 42:310-316.
106. Torriani FJ, Rockstroh J, Rodriguez-Torres M, et al. Final results of APRICOT: a randomized, partially blinded, international trial evaluating peginterferon-alpha-2a + ribavirin vs interferon-alpha-2a + ribavirin in the treatment of HCV in HIV/HCV co-infection. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections, 2004; San Francisco, CA.
107. Sulkowski MS, Dieterich DT, Bini EJ, et al. Epoietin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J AIDS 2005, 39:504-506.
108. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42:615-624.
109. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005, 142:105-114.
110. Cammà C, Giunta M, Andreone P, et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001, 34:593-602.
111. Wright TL Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002, 36:S185-S194.
112. Heathcote EJ, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1673-1680.
113. Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease. Am J Kidney Dis 2003, 42:631-657.
114. Tokars JI, Miller ER, Alter MJ, et al. National surveillance of dialysis-associated diseases in the United States, 1997. Semin Dial 2000, 13:75-85.
115. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000, 11:1896-1902.
116. Fabrizi F, Poordad FF, Martin P Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002, 36:3-10.
117. Russo MW, Goldsweig CD, Jacobson IM, et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003, 98:1610-1615.
118. Russo MG, Sigal R, Joshi SH, et al. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (peg-intron) in patients with chronic hepatitis C and end stage kidney disease on dialysis. Hepatology 2004, 40:399A.
119. Bruchfeld A, Lindahl K, Soderberg M, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003, 18:1573-1580.
120. Narayan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of post-transplantation recurrence of hepatitis C with interferon and ribavirin; lessons on tolerability and efficacy. Liver Transplant 2002, 8:623-629.
121. Sanchez-Tapias JM, Diago M, Escartin P, et al. Longer treatment duration with peginterferon alfa-2A (40kd) (Pegasys®) and ribavirin (Copegus®) in naive patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter TeraViC-4 study. Hepatology 2004, 40:218A.
122. Berg T, von Wagner M, Hinrichsen H, et al. Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1. Hepatology 2003, 38:317A.
123. von Wagner M, Huber M, Berg T, et al. Peginterferon alfa-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005, 129:522-527.
124. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004, 40:1260-1265.
125. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005, 352:2609-2617.
126. Bain V, Kaita K, Yoshida E, et al. A phase 2 study to assess antiviral response, safety, and pharmacokinetics of albuferon in IFN-alfa naive subjects with genotype 1 chronic hepatitis C. J Hepatol 2005, 42:9.
127. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoietin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004, 126:1302-1311.
128. Gish RG, Nelson D, Arora S, et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a. J Hepatol 2005, 42:39.
129. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
130. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
131. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004, 127:1347-1355.
132. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005, 41:832-835.
133. Reesink HW, Zeuzem S, van Vliet A, et al. Initial results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Gastroenterology 2005, 128(suppl.2):A-697.
134. Afdhal N, Rodrriguez-Torres M, Lawitz E, et al. Enhanced antiviral efficacy for valopicitabine (NM283) plus PEG-interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial. J Hepatol 2005, 42:39-40.
135. Afdhal N, Godofsky E, Dienstag J, et al. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 2004, 40:726A.
136. Krueger M, Beger C, Wong-Staal F Use of ribozymes to inhibit gene expression. Methods Enzymol 1999, 306:207-225.
137. Gordon SC, Bacon BR, Jacobson IM, et al. Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks. Hepatology 2003, 38:306A-307A.
138. Seo MY, Abrignani S, Houghton M, et al. Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol 2003, 77:810-812.
139. Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003, 38:1289-1296.
140. Manns MP, Berg T, Wedemeyer H, et al. Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non-responder patients. Hepatology 2004, 40:251A.